Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants

Table 3 Comparison of PDE-5 use between groups

	Study Group (n = 866)	Control Group (n = 11,436)	Total (n = 12,302)	Group differences
PDE-5 Inhibitor Use	74 (8.5%)	286 (2.5%)	360 (2.9%)	χ²₍₁₎ = 103.5, p < 0.001
Number of PDE-5 Inhibitors Used
One			187 (51.9%)
Two			115 (31.9%)
Three			58 (16.1%)
Types of PDE-5 Inhibitors Used—n (%)
Sildenafil			245 (68.1%)
Tadalafil			173 (48.1%)
Vardenafil			173 (48.1%)

ISSN: 1744-859X